All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vafidemstat
Therapeutic Area: Psychiatry/Psychology Product Name: ORY-2001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
PORTICO is a multicenter, double-blind, randomized, placebo-controlled Phase IIb trial to evaluate the efficacy and safety of vafidemstat in BPD patients. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in Phase II clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vafidemstat
Therapeutic Area: Psychiatry/Psychology Product Name: ORY-2001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
Details:
In the trial, vafidemstat was well tolerated and did not produce any severe adverse events (SAEs) in either the Single Ascending Dose or Multiple Ascending Dose parts.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vafidemstat
Therapeutic Area: Psychiatry/Psychology Product Name: ORY-2001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
PORTICO is a multicenter, double-blind, randomized, placebo-controlled Phase IIb trial to evaluate the efficacy and safety of vafidemstat in BPD patients with agitation/aggressiveness.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vafidemstat
Therapeutic Area: Psychiatry/Psychology Product Name: ORY-2001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
ORYZON has presented the final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020, Results demostrate that Vafidemstat reduces aggression in the three psychiatric disorders studied.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vafidemstat
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Spanish Ministry of Science and Innovation
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2020
Details:
Oryzon's project “VENCER: Vafidemstat Efficacy in the treatment against Schizophrenia and other related pathologies has been approved for funding by the Spanish Ministry of Science and Innovation under the 2019 call of the governmental R&D “RETOS-COLABORACION” program.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
